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Protocol
AbstrACt
Introduction Patient-reported outcomes (PROs) are 
increasingly included within cancer clinical trials. If 
appropriately collected, analysed and transparently 
reported, these data might provide invaluable evidence to 
inform patient care. However, there is mounting indication 
that the design and reporting of PRO data in cancer 
trials may be suboptimal. This programme of research 
will establish via three interlinked studies whether these 
findings are applicable to UK cancer trials, and if so, how 
to best enhance the way PROs are assessed, managed 
and reported in clinical trials. This study will explore 
with key stakeholders factors that influence optimal PRO 
protocol content, implementation and reporting and make 
recommendations for training and guidance.
Methods and analysis Semistructured interviews will be 
conducted with members of key stakeholder groups. The 
purposive sample of up to 48 participants will include: (1) 
trial chief investigators, trial management group members, 
statisticians and research nurses of cancer trials including 
primary or secondary PRO recruited via the National Cancer 
Research Institute (NCRI) Clinical Studies Group and Consumer 
Liaison Group and the UK Clinical Research Collaboration 
Registered UK Clinical Trial Unit Network; (2) NCRI Consumer 
Liaison Group members; (3) international experts in PRO 
oncology trial design; and (4) journal editors and funding 
bodies. Data will be analysed using directed thematic 
analysis employing a coding frame and modified as analysis 
progresses. Formal triangulation of coding and member 
checking will be employed to enhance credibility.
Ethics and dissemination This study was approved 
by the University of Birmingham Ethics Committee 
(Ref: ERN_17–0085). Findings will be disseminated via 
conference presentations, peer-reviewed journals, patient 
groups and social media (@CPROR_UoB; http://www. 
birmingham. ac. uk/ cpror).
PrOsPErO registration number CRD42016036533.
IntrOduCtIOn 
Patient-reported outcomes (PROs) are 
increasingly included within cancer clinical 
trials to provide the patient perspective on the 
physical, functional and psychological conse-
quences of treatment and the degree and 
impact of disease symptoms.1 The number 
of randomised controlled clinical trials 
including PROs is now substantial across all 
cancer disease sites, and these often include 
PROs as secondary endpoints.2 PROs are 
typically collected using multidimensional 
questionnaires in electronic or paper format 
and are completed by patients while they are 
participating in clinical trials. The results 
provide information about the symptoms or 
quality of life effects of a particular therapy 
strengths and limitations of this study
 ► This novel study will capture perspectives on the 
barriers and enablers of optimal PRO practice 
from a comprehensive range of stakeholders with 
experience of patient-reported outcome (PRO) data 
collection and reporting.
 ► The semistructured interview format ensures a 
replicable process while allowing sufficient freedom 
to explore new and emerging concepts.
 ► The recruitment strategy involves seeking 
participants through networks occupied by 
Evaluation of Patient-Reported Outcome (PRO) 
Protocol Content and Reporting in UK Cancer Clinical 
Trials Senior Management Group members. However, 
any limitation to sample representativeness and 
diversity will be mediated through the use of other 
recruitment avenues including the authorship lists of 
the protocols/publications included in phase I.
 ► Study is at risk of self-selection and social 
desirability bias. Participants are likely to take part if 
they have a pre-existing interest in PROs specifically 
and when recounting their experiences and insights 
are likely to wish to portray themselves in a positive 
manner due to the nature of this study.  on
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and may inform future treatment choices and help physi-
cians and patients decide the most suitable treatment and 
care for the individual. Rigorous study design and stan-
dardised data collection methods are required to collect 
the highest quality PRO data and adhering to good prac-
tice minimises errors, measurement variability, missing 
data and systematic bias, upholding trial validity.3 
The use of PROs in cancer clinical trials has been 
exhorted by major international health policy and regu-
latory authorities as well as patients with cancer.4–6 PRO 
trial results inform clinical decision making; health tech-
nology assessment; health economic evaluations; label-
ling claims; healthcare policy; and commissioning7–10 
when rigorously captured. PRO data can enhance clini-
cian–patient communication relating to treatment 
options and contribute to complex healthcare decision 
making11 12 by providing information on relative benefits 
and side effects of new drugs or treatment options.13–17 
Using this information, patient–clinician consultations 
may result in more informed choices, positive results and 
favourable experiences of care.18 19 As such, guidance 
included in trial protocols must ensure appropriate PRO 
data collection and management,20 21 and results must 
be fully reported in resulting publications so that PRO 
information is readily publicly accessible to patients and 
integrated into clinical practice and policy.21
Recent international evidence,22–25 however, suggests 
PRO information is often omitted from protocols, leading 
to impaired data collection. Such research also suggests 
that PRO results are poorly reported in trial publications, 
or may not be reported at all.22 Our previous review of 75 
National Institute for Health Research Health Technology 
Assessment trials23 found that relevant PRO information 
is commonly omitted from trial protocols, even where a 
PRO is the primary outcome. As a result, PRO data may 
not be used effectively to inform patient–clinician deci-
sion making at the point of diagnosis and beyond. This 
represents a waste of limited healthcare and research 
resources, devalues the contribution of trial participants 
providing PRO data and has serious ethical implications.
While there has been some qualitative research inves-
tigating PRO administration in trials,24 26 there has been 
little qualitative work investigating the factors affecting 
PRO trial design, protocol development and reporting.
The Evaluation of Patient-Reported Outcome (PRO) 
Protocol Content and Reporting in UK Cancer Clinical 
Trials (EPiC) study is a mixed method study investigating 
PRO protocol content and reporting in UK cancer clin-
ical trials aiming to identify factors that enable and inhibit 
good practice. The research will take place over three 
stages; the methods pertaining to phase I are presented 
in detail elsewhere.27
This paper provides a summary of the phase II qual-
itative component, in which semistructured interviews 
will be conducted to explore the potential barriers and 
enablers relating to optimal PRO protocol content, imple-
mentation and reporting with cancer trialists, research 
nurses (RNs), consumer representatives, international 
experts, journal editors and funders. Through the inclu-
sion of individuals from each of these groups, the collec-
tion and reporting of PRO data can be considered by 
the individuals involved at every phase of the research 
process—including study conception and design and 
patients’ experiences of providing PRO data as trial 
participants—until the point at which results are commu-
nicated. Phase III of the study will incorporate findings 
and examples of best practice from both phases I and II 
into our publicly accessible, web-based training resource 
(www. birmingham. ac. uk/ prolearn).
AIMs
Semistructured telephone and face-to-face interviews will 
be conducted (AR) to explore the perspectives and expe-
rience of key stakeholders in relation to:
1. the potential barriers and enablers to optimal PRO 
protocol content, implementation and reporting
2. the PRO-specific training needs of each stakeholder 
group
3. the optimal methods of implementing such training 
and ensuring uptake of both the forthcoming SPIRIT-
PRO28 and published CONSORT-PRO29 guidelines.
PArtICIPAnts And sEttIng
The primary inclusion criteria are that participants must 
have experience of designing or reviewing clinical trials 
including PROs within a professional capacity or comple-
tion of PROs through participation in a trial. Interviewees 
will be sampled from four groups: (1) trial chief inves-
tigators, trial management group members, statisticians 
and RNs with experience of involvement in a cancer trial 
including primary or secondary PRO; (2) National Cancer 
Research Institute (NCRI) Consumer Liaison Group 
members with experience of involvement in the design 
of trials with PRO endpoints; (3) international experts in 
PRO oncology trial design, including members of multi-
country cancer and quality of life research organisations, 
national regulatory bodies, advisory bodies and global 
corporations; and (4) journal editors and key represen-
tatives from funding bodies. Based on the experience of 
the research team, it is anticipated that recruitment of 
approximately 8–12 individuals from each group will be 
required to reach data saturation. Thus, up to 48 partic-
ipants may be required. Individuals will be purposively 
selected based on having occupied a role within trials in 
management, data collection, as a patient partner or a 
participant. The categorisation of participants into the 
above four groups will allow the research team to attain 
maximum variation with regards to experience and role. 
Recruitment will continue for each distinct group until 
data saturation is achieved.
Group 1 will be identified from: (1) the author-
ship lists of the trial protocols/publications included 
in phase I or (2) NCRI Clinical Studies Groups 
and Consumer Liaison Group and the UK Clinical 
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Research Collaboration Registered UK Clinical Trial 
Unit (UKCRC-UKCTU) Network, facilitated by an 
EPiC study management member who is also the 
UKCRC-UKCTU network director. Trials from phase 
I will be purposively selected to ensure representa-
tion across the following criteria: clinical area, SPIR-
IT-PRO and CONSORT-PRO checklist score23 28–30 and 
funding source. Group 2 participants will be identified 
via the NCRI Consumer Liaison Group, facilitated by 
an EPiC study management member who is also the 
NCRI Psychosocial Oncology and Survivorship Clinical 
Studies Group chair. Group 3 will be identified using 
the personal contacts of the study management group, 
in particular via an EPiC study senior management 
group member who is also director of the Centre for 
Patient-Reported Outcomes Research at the Univer-
sity of Birmingham. Group 4 will be identified using 
publicly available information via the appropriate 
journal/funder website.
dAtA COllECtIOn
Potential participants will be approached via email 
(either directly where contact details are in the public 
domain or via the centre from which they were iden-
tified where appropriate) and provided with a brief 
outline of the project aims, the consent form and infor-
mation sheet and details of how to register interest. 
Individuals interested in taking part will be contacted 
by the research fellow (AR) and will be given an 
opportunity to ask further questions before deciding 
whether to take part in the study. An interview date will 
be set for those wishing to participate. Participants will 
be first offered a telephone interview. In cases where 
the individual wishes to participate in an interview but 
would prefer to do so in person rather than via tele-
phone, this will be arranged if feasible.
Participants will be sent a consent form to complete. 
The researcher will request that the consent form 
is returned prior to the interview. In cases where a 
consent form has not been received by the researcher 
in advance of the interview, verbal consent will be 
audio-recorded and taken via a standardised script 
immediately prior to the interview. If a participant 
would prefer their verbal consent is not audio-re-
corded, verbal consent will still be taken prior to inter-
view but on the understanding that a consent form will 
be sent by the researcher to the participant immedi-
ately after the interview to be signed and returned.
The interviews will last for approximately 1 hour. 
Participants will be interviewed using a predefined 
topic guide (online supplementary appendix 1) with 
sufficient scope to explore novel themes where appro-
priate and will be audio-recorded. Interview record-
ings will be professionally transcribed verbatim. All 
participants will remain anonymous, and all data will 
be treated as confidential.
Study dates: March 2016–September 2018.
AnAlysIs
Interview transcripts will be analysed using directed 
thematic analysis (AR) whereby findings from previous 
qualitative and review work24 and the analysis of included 
protocols and publications from phase I will be used in 
addition to developing an initial coding framework.31 
Additional codes will be developed as the analysis 
progresses and the framework will be modified accord-
ingly.31 Formal triangulation of coding will be employed 
to enhance the credibility of the analysis. This will be 
undertaken at regular intervals during analysis when a 
subsample of transcripts will be coded by an additional 
researcher (DK/MC), and differences will be discussed to 
ensure intercoder agreement.
The findings from this phase, in combination with the 
phase I findings, will be used in phase III to highlight 
examples of best practice in PRO protocol design and 
reporting and inform the development of an online PRO 
training resource.
dIssEMInAtIOn
The results of this study will be disseminated via presen-
tations at local, national and international conferences, 
peer-reviewed journals and through social media including 
the Centre for Patient Reported Outcomes Research’s 
Twitter account and the University of Birmingham 
departmental website (http://www. birmingham. ac. uk/ 
cpror), as well as the NCRI (including the consumer 
forum), Macmillan Cancer Support and via international 
cancer trial groups. Participants will be anonymised, and 
all data collected will be treated as confidential. Only 
anonymised, non-identifiable characteristics and quotes 
will be used in any arising publications/reports.
PrOtOCOl And rEgIstrAtIOn
This study protocol for the wider programme of work is 
registered on PROSPERO (CRD42016036533). Registra-
tion details are available at http://www. crd. york. ac. uk/ 
PROSPERO/ display_ record. asp? ID= CRD42016036533.
dIsCussIOn
Existing evidence and pilot data collected to demon-
strate the feasibility of our approach suggests there may 
be substantial variation in PRO protocol content and 
reporting in UK cancer clinical trials. The qualitative 
component of the EPiC study will explore and explain the 
contributing factors with stakeholders and establish how 
clinical trial practice may be improved and supported 
through training and other resources. This work could 
benefit several groups including researchers and those 
involved in research dissemination and service delivery. 
Appropriate collection, analysis, rationale and reporting 
of PROs may result in comprehensive data on which 
treatment decisions may be based, benefiting patients, 
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but would also promote more effective use of public and 
charitable funds.
This work represents the PRO component within a 
far wider effort to promote effective, robust and trans-
parent practice within clinical trials. Initiatives focusing 
on improving practice relating to various aspects of clin-
ical trials32–34 have been lauded and are changing prac-
tice through their use.35–37 The inconsistent use of PROs 
in cancer clinical trials is well documented; however, 
the findings from this programme of research have the 
potential to address these shortcomings through the 
development of tailored PRO training and guidance for 
key stakeholders.
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